Business Wire

Large-Scale Body Composition Study Reveals Link between Specific Fat Distributions and Metabolic Diseases

Del

Specific patterns of fat distribution are linked to the presence of Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D), according to a new study published in Obesity. 1 AMRA, the international leader in body composition analysis, today announced the results of a body composition study of over 6,000 subjects, stressing the need to measure and investigate several fat compartments in order to understand and develop treatments for multiple metabolic diseases. The new findings go far beyond what can be described by sex, age, lifestyle, BMI, or a single fat compartment, and have the potential to strongly impact how metabolic conditions will be prevented and managed in the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005616/en/

The Obesity study was co-authored in collaboration between AMRA, Pfizer, Westminster University, Linköping University, and UK Biobank. The 6,000 subjects analyzed are part of the UK Biobank Imaging Study, a major national and international health resource. In 2015, UK Biobank announced that AMRA would perform the automated analysis of MRI images for precise fat and muscle measurements. AMRA has now developed the technique of body composition profiling, which allows for precise analysis of multiple variables to describe the complex associations and interactions between fat distribution, muscle volumes, and metabolic status.

Regardless of normal, overweight, or obese BMI class, AMRA’s body composition profiling of the subjects revealed a number of skewed fat distribution patterns, or phenotypes, that cannot be described when looking at a single fat or muscle measurement. These phenotypes are associated with different metabolic disease profiles: some exhibit no metabolic disease, while others exhibit CHD, T2D, or the co-morbidity of the two. Specifically, higher visceral fat and muscle fat was associated with CHD and T2D (p<0.001) while higher liver fat was associated with T2D (p<0.001) and lower liver fat with CHD (p<0.05). Lower visceral fat and muscle fat was also associated with metabolic health (p<0.001), whereas liver fat was non-significant. Associations remained significant when adjusting for sex, age, BMI, alcohol, smoking, and physical activity.

Dr Olof Dahlqvist Leinhard, senior author of the study, commented, “It has been known for some time that there are fat distributions that are disadvantageous from a health perspective. Today, new techniques provide high accuracy and precision, enabling in-depth analyses of the clinical importance of body composition at a large scale. What’s exciting is that, by using a multivariable approach and an intuitive visualization of body composition, we’ve been able to identify a wide range of body composition profiles that could provide the link to increased risk of metabolic diseases.”

Tommy Johansson, Chief Executive Officer of AMRA, added, “These ground-breaking results allow a glimpse into the future where precision diagnostics will provide the backbone to personalized medicine. By better understanding of muscle and fat volumes, and where fat is located in the body, we hope to help redefine disease risk and suitability for treatment. Our vision is that, in the future, our research and technology will be used to assist in the improved prevention, diagnosis, and treatment of a wide range of diseases.”

Today a quarter of the world’s adults have Metabolic Syndrome – a cluster of factors that increase the risk of several chronic diseases, such as heart disease, cancer, stroke, liver disease and diabetes.2 Obesity, CVD and T2D are growing pandemics and leading causes of early death globally, presenting some of the greatest challenges to patients and healthcare systems worldwide.3,4,5,6

-ENDS-

Study detail

The first 6,021 participants from the UK Biobank imaging sub-study – mean age 62.3±7.5 years, and BMI 26.7±4.4 kg/m2 – were scanned using a 6-minutes MRI protocol providing a water and fat separated volumetric dataset covering neck to knees, and a single slice for proton density fat fraction (PDFF) assessment in the liver. For body composition, acquired image data were analyzed for visceral adipose tissue, abdominal subcutaneous adipose tissue, thigh muscle volume, muscle fat infiltration in the anterior thighs, and liver PDFF. Briefly, the image analysis comprised of (1) image calibration, (2) fusion of image stacks, (3) image segmentation, (4) quantification of fat and muscle volumes7,8,9,10,11 and manual quality control by an analysis engineer.

Diagnosis information was gathered through in-patient electronic healthcare records and via touchscreen questionnaires followed by interviews performed by trained nurses. For CHD and T2D, two matched control groups were stratified matched on (1) sex and age, and (2) sex, age, and BMI. Participants were considered metabolic disease free if they did not report any conditions considered to be serious enough to represent metabolically-focused health concerns (e.g. cardiovascular and metabolic diseases, severe chronic conditions, neurological diseases, and cancers).12

The study was carried out as a collaboration between AMRA medical, Pfizer, Westminster University and Linköping University. Funding support was provided by Pfizer.

About AMRA

AMRA is the first in the world to transform images from a rapid, 6-minute whole body MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA’s cloud-based analysis service offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit www.amramedical.com.

About UK Biobank

UK Biobank is a major national and international health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40–69 years in 2006–2010 from across the country, when they provided lots of information about their health and well-being and donated samples of blood and urine for long-term storage and analysis, including genetic information. The project has permission to follow participants’ health through medical records. UK Biobank has also embarked on a major project to MRI scan the vital internal organs and body composition of 100,000 participants. Over many years, these detailed data will build a powerful resource to help scientists discover why some people develop particular diseases and others do not, and to suggest new ways of preventing and treating them.

1 http://onlinelibrary.wiley.com/doi/10.1002/oby.22210

2 Worldwide Definition of the Metabolic Syndrome, International Diabetes Federation (IDF)

3 Chang S-H, et al. JAMA Surg 2014;149:275–87

4 IDF diabetes atlas. 2015. Available at: http://www.diabetesatlas.org [last accessed 06.10.16]

5 Branca F, et al. The Challenge of Obesity in the WHO European Region and the Strategies for Response: Summary. 2007

6 Klein S, et al. Obesity (Silver Spring) 2011;19:581–7

7 West J, Dahlqvist Leinhard O, Romu T, et al. Feasibility of MR-based Body Composition Analysis in Large Scale Population Studies. PLoS ONE 2016;11(9)

8 Borga M, Thomas EL, Romu T, et al. Validation of a Fast Method for Quantification of Intra-abdominal and Subcutaneous Adipose Tissue for Large Scale Human Studies. NMR Biomed 2015;28(12):1747–53

9 OD Leinhard, A Johansson, J Rydell, et al. Quantitative Abdominal Fat Estimation Using MRI Pattern Recognition. In: Proceedings of the 19th International Conference on Pattern Recognition (ICPR) 08–11 Dec, 2008; Tampa, FL

10 Karlsson A, Rosander J, Romu T, et al. Automatic and Quantitative Assessment of Regional Muscle Volume by Multi-Atlas Segmentation Using Whole-Body Water-Fat MRI. JMRI 2015;41(6):1558–69

11 West J, Romu T, Thorell S, et al.. Precision of MRI-based body composition measurements of postmenopausal women. PLoS One 2018;13(2):e0192495

12 UK Biobank Data Showcase. Available at: http://biobank.ctsu.ox.ac.uk/crystal/ [last accessed 16.11.17]

Contact information

AMRA Medical AB
Chelsea Ranger
SVP Commercial & Market Strategy
chelsea.ranger@amramedical.com
or
UK Biobank
Andrew Trehearne
Head of Communications
andrew.trehearne@ukbiobank.ac.uk

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13Pressemelding

Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced

Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41Pressemelding

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo

Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46Pressemelding

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+

Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16Pressemelding

HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati